Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion

The drug nitisinone (NTBC; Orfadin, Vienna, Austria) has been used for the treatment of hereditary tyrosinemia type‐1 since 1991. Nitisinone effectively blocks the metabolism of tyrosine to prevent the formation of the toxic compound succinylacetone (and precursor fumarylacetoacetate) in affected ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Jack, Rhona M., Scott, C. Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498826/
https://www.ncbi.nlm.nih.gov/pubmed/31240158
http://dx.doi.org/10.1002/jmd2.12023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498826/
https://www.ncbi.nlm.nih.gov/pubmed/31240158
http://dx.doi.org/10.1002/jmd2.12023

Ejemplares similares